Abaloparatide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Abaloparatide is an FDA-approved bone-building shot for women past menopause with bone thinning.
Evidence grade for Abaloparatide: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 1 completed trial, 2,463 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 2,463
- Human studies
- 1
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved (Tymlos) for osteoporosis
3 effects reported, 2 unwanted, 1 wanted, by people using it, not a trial
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Abaloparatide is a daily shot that builds new bone. It copies a protein related to parathyroid hormone. It is sold as Tymlos for women past menopause with thin bones who are at high risk of breaking one. It is approved and prescription only.
What people take it for
- Fewer broken bones in severe bone thinning.
- Building bone back, not just slowing the loss.
What studies in people showed
The biggest study had 2,463 women past menopause for 18 months. Spine fractures and other fractures were less common than on a dummy shot. High blood calcium, a known problem with this kind of drug, happened less often than on teriparatide. After that, the women took alendronate, a bone pill, for two more years. Over 43 months in total, spine fractures hit 0.9 percent of the drug group and 5.6 percent of the others. That credit goes to the two drugs in a row, not one alone.
What people report
Reports, not study results
The good
- Fewer broken bones in the studies on this page.
The bad
- High blood calcium can happen with this kind of drug, though it was less common than on teriparatide in its study.
- A shot every day.
Where these come from: Everything here is from the two human studies on this page. We have not collected forum or user reports for this one yet.
My bottom line
Another real bone builder with real fracture results. If your bone scan is bad, it is worth asking your doctor about. Keep training too.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Nothing indexed yet
The 2 citations on this page do not report a result for any of the 36 goals indexed here. Most of what sits here is something else: a listing of a planned study, a study of how the body handles the drug, a safety report or a government record. None of those tests whether it works.
Show full evidence
What is Abaloparatide?
Abaloparatide is an FDA-approved bone-building shot for women past menopause with bone thinning.
Abaloparatide is a lab-made copy of a protein related to parathyroid hormone. It is approved as Tymlos to build bone in women past menopause who are at high risk of breaking a bone. Like teriparatide, it is a daily shot that builds new bone. It works on the same receptor, but in a way that favours building bone over breaking it down. The big study, ACTIVE, had 2,463 women for 18 months. New spine fractures and other fractures were less common than on a dummy shot. High blood calcium happened less often than on teriparatide. In the follow-on, women took alendronate, a bone pill, for 24 months after the shots. Over 43 months, spine fractures hit 0.9% of the abaloparatide group and 5.6% of the others.
How does Abaloparatide work?
It switches on the PTH1 receptor in a way that favours building bone over breaking it down. That raises bone density.
The evidence, in charts
Fig. 1a · how many people
2,463people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| ACTIVE, JAMA 2016 | 2,463 | 100% |
The whole total is one study of 2,463. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2016 and 2018.
Too few different years on this page to draw a timeline. The newest source on file is from 2018, more than five years ago. Research on it may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- 3,961 Da
- Half-life
- About 1 hoursShort, 1 to 6 hours
- Chain length
- None on file
No amino acid sequence is on file for Abaloparatide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2016Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial (ACTIVE)
A newer bone building injection also prevented fractures. Nearly two and a half thousand women past the menopause took abaloparatide or a dummy injection for a year and a half. Fractures in the spine and elsewhere were less common on the drug. Raised blood calcium, a known nuisance with this kind of drug, happened less often than with teriparatide. This trial ran eighteen months, so it says nothing about taking the drug for years.
2,463 women over 18 months: abaloparatide reduced new vertebral and nonvertebral fractures versus placebo with less hypercalcemia than teriparatide.
- Study in people2018ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis
Following the injection with a common bone tablet kept the protection going for years. Women who had taken abaloparatide, or a dummy, then took alendronate for two more years. Across nearly four years in total, fewer than one in a hundred of the abaloparatide group had a spine fracture, against about six in a hundred of the others. That is roughly five fractures prevented for every hundred women. This is a sequence of two drugs, so neither gets the credit alone.
Over 43 months, vertebral fractures 0.9% versus 5.6% (84% relative risk reduction) for abaloparatide then alendronate.
Where to buy Abaloparatide
Abaloparatide is an approved medicine. The approved product comes from a pharmacy, with a prescription. The vials below are sold “for research” and are not the approved drug.
2 sellers list Abaloparatide in our latest read. They are ranked by trust score, then by archive rating, then by certificate tier, then by the lowest price per milligram. Archive evidence is counted before source-backed. Each path is out of 4, and the two are not added. A higher price does not raise the score. The letter is the certificate chip. 0 of them have a published certificate that names Abaloparatide.
Some seller links may pay this site when you buy through them. A payment never changes a seller's tier or rank, and no seller has a say in any page.
| Seller | Trust score | Vial sizes | From, per mg | Certificate for Abaloparatide | Seller link |
|---|---|---|---|---|---|
| Zenergy USA | 49 WeakSource-backed 3 of 4. Archive evidence 2 of 4.A | 3 mg | $29.7 | None found for Abaloparatide | View |
| Boston Molecules | 28 InsufficientSource-backed 1 of 4. Archive evidence 1 of 4.C | 10 mg | $81.0 | None found for Abaloparatide | View |
- LC Lab-confirmed: the issuing laboratory echoed this certificate back
- A Current certificate, independent laboratory named, laboratory not yet checked
- B Certificate published, but no laboratory link, older than a year, or the laboratory did not recognise the published lookup
- C No certificate could be read
Every listing and vial size for Abaloparatide · How the trust score is counted
Sellers named on the price pages are ranked by certificate tier, then price, and any affiliate income is disclosed there. Naming a seller is not a recommendation to buy or use anything.
Common questions
Has Abaloparatide been tested in people?
Yes. 2,463 people given it across 1 completed trial cited here, 0 of which found nothing. Abaloparatide is an FDA-approved bone-building shot for women past menopause with bone thinning.
What is the Abaloparatide dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA-approved (Tymlos) for osteoporosis
Is Abaloparatide FDA-approved?
FDA-approved (Tymlos) for osteoporosis
How does abaloparatide compare to teriparatide?
Both are daily bone-building shots. Abaloparatide is based on a protein related to parathyroid hormone. Teriparatide is based on parathyroid hormone itself. Both cut fractures in people at high risk.